Clinical Trial Update: Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant Patients [Phase 2]

View source ↗

Summary

Phase 2 study of a JAK3 inhibitor for preventing acute rejection in kidney transplant recipients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• JAK3 inhibitor (JAK3 inhibitor)

Snippet

Sponsor: Pfizer | Conditions: Kidney Transplantation | Phase 2 | Status: WITHDRAWN